April 03, 2026 01:00 am (IST)
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Sensex recovers from over 1,500-point crash to end higher; Nifty rebounds amid Iran tensions
Thu, Apr 02 2026
Market mayhem: Trump’s Iran strike warning rattles Dalal Street, Sensex crashes 1,500 pts
Thu, Apr 02 2026
Fuel prices rise: Premium petrol, diesel hiked amid oil price surge
Wed, Apr 01 2026
Defence PSU boom! Garden Reach Shipbuilders & Engineers stock rockets 20%—what’s driving the surge?
Wed, Apr 01 2026
Dalal Street on fire: Sensex soars, Nifty rockets—here’s why!
Wed, Apr 01 2026
Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India
Wed, Apr 01 2026
